Trials / Completed
CompletedNCT04948411
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Latin American Cooperative Oncology Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil
Conditions
Timeline
- Start date
- 2021-09-30
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
- First posted
- 2021-07-02
- Last updated
- 2024-02-21
Locations
4 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04948411. Inclusion in this directory is not an endorsement.